Skip to main content
Top
Published in: Cancer Cell International 1/2015

Open Access 01-12-2015 | Primary research

RhoGDI2 up-regulates P-glycoprotein expression via Rac1 in gastric cancer cells

Authors: Zhong Zheng, Bingya Liu, Xiaohua Wu

Published in: Cancer Cell International | Issue 1/2015

Login to get access

Abstract

Multidrug resistance (MDR) is a major clinical obstacle in treatment of gastric cancer. Previously, using 2D electrophoresis-mass spectrometry, we identified RhoGDI2 as a contributor to 5-FU resistance in colon cancer cells, and also confer gastric cancer cells resistance to 5-FU. Here, we reported RhoGDI2 also induced MDR in gastric cancer cell line (MKN-45). To explore the underlining mechanism, we detected the mRNA, protein expression, activity of P-glycoprotein (P-gp) in MKN-45 stably transfected with RhoGDI2 expressing or control vector. All the mRNA, protein level, activity were increased by 130%, 230%, 35% respectively after ectopic expression of RhoGDI2. RhoGDI2 was correlated with P-gp expression in gastric cancer tissues as detected by immunohistochemistry. To further study how RhoGDI2 up-regulates P-gp expression, we tested the activity of Rac1 in MKN-45/RhoGDI2 and MKN-45/GFP. Ectopic expression of RhoGDI2 increased Rac1 activity (P < 0.05). For more important, silencing of Rac1 expression by siRNA decreased P-gp expression to undetectable level. Overall, these findings suggest that RhoGDI2 up-regulates P-gp expression via Rac1 to induce MDR.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed
2.
go back to reference Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–8.CrossRefPubMed Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–8.CrossRefPubMed
3.
go back to reference Zhang D, Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol. 2010;6(4):527–37.CrossRefPubMed Zhang D, Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol. 2010;6(4):527–37.CrossRefPubMed
4.
go back to reference Zheng Z, Li J, He X, Chen X, Yu B, Ji J, et al. Involvement of RhoGDI2 in the resistance of colon cancer cells to 5-fluorouracil. Hepatogastroenterology. 2010;57(102-103):1106–12.PubMed Zheng Z, Li J, He X, Chen X, Yu B, Ji J, et al. Involvement of RhoGDI2 in the resistance of colon cancer cells to 5-fluorouracil. Hepatogastroenterology. 2010;57(102-103):1106–12.PubMed
5.
go back to reference Cho HJ, Baek KE, Nam IK, Park SM, Kim IK, Park SH, et al. PLCgamma is required for RhoGDI2-mediated cisplatin resistance in gastric cancer. Biochem Biophys Res Commun. 2011;414(3):575–80.CrossRefPubMed Cho HJ, Baek KE, Nam IK, Park SM, Kim IK, Park SH, et al. PLCgamma is required for RhoGDI2-mediated cisplatin resistance in gastric cancer. Biochem Biophys Res Commun. 2011;414(3):575–80.CrossRefPubMed
6.
go back to reference Cho HJ, Baek KE, Park SM, Kim IK, Nam IK, Choi YL, et al. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression. Cancer Lett. 2011;311(1):48–56.CrossRefPubMed Cho HJ, Baek KE, Park SM, Kim IK, Nam IK, Choi YL, et al. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression. Cancer Lett. 2011;311(1):48–56.CrossRefPubMed
7.
go back to reference Cho HJ, Kim IK, Park SM, Baek KE, Nam IK, Park SH, et al. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance. Int J Cancer. 2014;135(7):1553–63.CrossRefPubMed Cho HJ, Kim IK, Park SM, Baek KE, Nam IK, Park SH, et al. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance. Int J Cancer. 2014;135(7):1553–63.CrossRefPubMed
8.
go back to reference Kim IK, Park SM, Cho HJ, Baek KE, Nam IK, Park SH, et al. 14-3-3sigma attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells. Oncotarget. 2013;4(11):2045–56.PubMedCentralPubMed Kim IK, Park SM, Cho HJ, Baek KE, Nam IK, Park SH, et al. 14-3-3sigma attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells. Oncotarget. 2013;4(11):2045–56.PubMedCentralPubMed
9.
go back to reference Zheng Z, He XY, Li JF, Yu BQ, Chen XH, Ji J, et al. RhoGDI2 confers resistance to 5-fluorouracil in human gastric cancer cells. Oncology Letters. 2013;5(1):255–60.PubMedCentralPubMed Zheng Z, He XY, Li JF, Yu BQ, Chen XH, Ji J, et al. RhoGDI2 confers resistance to 5-fluorouracil in human gastric cancer cells. Oncology Letters. 2013;5(1):255–60.PubMedCentralPubMed
10.
go back to reference Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol. 2008;9(9):690–701.CrossRefPubMed Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol. 2008;9(9):690–701.CrossRefPubMed
11.
12.
go back to reference Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J. 2005;390(Pt 1):1–9.PubMedCentralPubMed Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J. 2005;390(Pt 1):1–9.PubMedCentralPubMed
13.
go back to reference Zhang Y, Rivera Rosado LA, Moon SY, Zhang B. Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling. J Biol Chem. 2009;284(19):12956–65.CrossRefPubMedCentralPubMed Zhang Y, Rivera Rosado LA, Moon SY, Zhang B. Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling. J Biol Chem. 2009;284(19):12956–65.CrossRefPubMedCentralPubMed
14.
go back to reference Moissoglu K, McRoberts KS, Meier JA, Theodorescu D, Schwartz MA. Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Res. 2009;69(7):2838–44.CrossRefPubMedCentralPubMed Moissoglu K, McRoberts KS, Meier JA, Theodorescu D, Schwartz MA. Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Res. 2009;69(7):2838–44.CrossRefPubMedCentralPubMed
15.
go back to reference Agarwal NK, Chen CH, Cho H, Boulbes DR, Spooner E, Sarbassov DD. Rictor regulates cell migration by suppressing RhoGDI2. Oncogene. 2013;32(20):2521–6.CrossRefPubMedCentralPubMed Agarwal NK, Chen CH, Cho H, Boulbes DR, Spooner E, Sarbassov DD. Rictor regulates cell migration by suppressing RhoGDI2. Oncogene. 2013;32(20):2521–6.CrossRefPubMedCentralPubMed
16.
go back to reference Griner EM, Theodorescu D. The faces and friends of RhoGDI2. Cancer Metastasis Rev. 2012;31(3-4):519–28.CrossRefPubMed Griner EM, Theodorescu D. The faces and friends of RhoGDI2. Cancer Metastasis Rev. 2012;31(3-4):519–28.CrossRefPubMed
17.
go back to reference Huang CY, Yang LC, Liu KY, Chang IC, Liao PH, Chou JI, et al. ZAK negatively regulates RhoGDIbeta-induced Rac1-mediated hypertrophic growth and cell migration. J Biomed Sci. 2009;16:56.CrossRefPubMedCentralPubMed Huang CY, Yang LC, Liu KY, Chang IC, Liao PH, Chou JI, et al. ZAK negatively regulates RhoGDIbeta-induced Rac1-mediated hypertrophic growth and cell migration. J Biomed Sci. 2009;16:56.CrossRefPubMedCentralPubMed
18.
go back to reference Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage H. Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis. 1999;20(14):2961–9.CrossRefPubMed Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage H. Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis. 1999;20(14):2961–9.CrossRefPubMed
19.
go back to reference Goto T, Takano M, Sakamoto M, Kondo A, Hirata J, Kita T, et al. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. Oncol Rep. 2006;15(5):1265–71.PubMed Goto T, Takano M, Sakamoto M, Kondo A, Hirata J, Kita T, et al. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. Oncol Rep. 2006;15(5):1265–71.PubMed
20.
go back to reference Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002;71:537–92.CrossRefPubMed Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002;71:537–92.CrossRefPubMed
21.
go back to reference Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8(5):411–24.CrossRefPubMed Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8(5):411–24.CrossRefPubMed
22.
go back to reference Griner EM, Dancik GM, Costello JC, Owens C, Guin S, Edwards MG, et al. RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer. Mol Cancer Res. 2015;13(3):483–92.CrossRefPubMed Griner EM, Dancik GM, Costello JC, Owens C, Guin S, Edwards MG, et al. RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer. Mol Cancer Res. 2015;13(3):483–92.CrossRefPubMed
24.
go back to reference Boulter E, Garcia-Mata R, Guilluy C, Dubash A, Rossi G, Brennwald PJ, et al. Regulation of Rho GTPase crosstalk, degradation and activity by RhoGDI1. Nat Cell Biol. 2010;12(5):477–83.CrossRefPubMedCentralPubMed Boulter E, Garcia-Mata R, Guilluy C, Dubash A, Rossi G, Brennwald PJ, et al. Regulation of Rho GTPase crosstalk, degradation and activity by RhoGDI1. Nat Cell Biol. 2010;12(5):477–83.CrossRefPubMedCentralPubMed
25.
26.
go back to reference Wu Y, Moissoglu K, Wang H, Wang X, Frierson HF, Schwartz MA, et al. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci U S A. 2009;106(14):5807–12.CrossRefPubMedCentralPubMed Wu Y, Moissoglu K, Wang H, Wang X, Frierson HF, Schwartz MA, et al. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci U S A. 2009;106(14):5807–12.CrossRefPubMedCentralPubMed
27.
go back to reference Ota T, Maeda M, Okamoto M, Tatsuka M. Positive regulation of Rho GTPase activity by RhoGDIs as a result of their direct interaction with GAPs. BMC Syst Biol. 2015;9:3.CrossRefPubMedCentralPubMed Ota T, Maeda M, Okamoto M, Tatsuka M. Positive regulation of Rho GTPase activity by RhoGDIs as a result of their direct interaction with GAPs. BMC Syst Biol. 2015;9:3.CrossRefPubMedCentralPubMed
28.
go back to reference Wang YW, Qu Y, Li JF, Chen XH, Liu BY, Gu QL, et al. In vitro and in vivo evidence of metallopanstimulin-1 in gastric cancer progression and tumorigenicity. Clin Cancer Res. 2006;12(16):4965–73.CrossRefPubMed Wang YW, Qu Y, Li JF, Chen XH, Liu BY, Gu QL, et al. In vitro and in vivo evidence of metallopanstimulin-1 in gastric cancer progression and tumorigenicity. Clin Cancer Res. 2006;12(16):4965–73.CrossRefPubMed
29.
go back to reference Yuen HF, Chan YP, Chan KK, Chu YY, Wong ML, Law SY, et al. Id-1 and Id-2 are markers for metastasis and prognosis in oesophageal squamous cell carcinoma. Br J Cancer. 2007;97(10):1409–15.CrossRefPubMedCentralPubMed Yuen HF, Chan YP, Chan KK, Chu YY, Wong ML, Law SY, et al. Id-1 and Id-2 are markers for metastasis and prognosis in oesophageal squamous cell carcinoma. Br J Cancer. 2007;97(10):1409–15.CrossRefPubMedCentralPubMed
30.
go back to reference Ben QW, Wang JC, Liu J, Zhu Y, Yuan F, Yao WY, et al. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2010;17(8):2213–21.CrossRefPubMed Ben QW, Wang JC, Liu J, Zhu Y, Yuan F, Yao WY, et al. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2010;17(8):2213–21.CrossRefPubMed
Metadata
Title
RhoGDI2 up-regulates P-glycoprotein expression via Rac1 in gastric cancer cells
Authors
Zhong Zheng
Bingya Liu
Xiaohua Wu
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2015
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-015-0190-4

Other articles of this Issue 1/2015

Cancer Cell International 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine